BPC-157: The Easy Guide for 2026

Research suggests BPC-157 may support healing in several ways:

• Growth hormone receptors: It increases growth hormone receptor expression in tissues.
• Blood vessel growth: It activates pathways involved in angiogenesis, the formation of new blood vessels that bring nutrients to injured tissue.
• Cell growth: It supports pathways linked to tissue repair.
• Inflammation: It reduces inflammatory cytokines.

Mostly Animal Studies

A 2025 systematic review in HSS Journal looked at all BPC-157 research in orthopaedic sports medicine. It found 36 studies:

The review concluded that BPC-157 shows promise for musculoskeletal injury recovery, but the evidence comes from low-level studies.

The Human Study

In the only human study in that review, 7 out of 12 people with chronic knee pain reported relief lasting more than six months after a single BPC-157 knee treatment.

This was a small study without a control group, so it can’t prove BPC-157 works.

The Bottom Line on Research

BPC-157 has a lot of promising animal research, but very little human data. Larger, controlled human trials are still needed.

We don’t know yet. No adverse effects were reported in the animal studies, but human safety remains unknown.

In its 2026 review, FDA staff noted they had received three adverse event reports linked to BPC-157, including one person with nine days of redness and swelling at the application site. The FDA said it was unclear whether BPC-157 caused these effects.

No. BPC-157 is not approved as a drug by the FDA or any other health authority.

BPC-157 FDA Timeline

What the 2026 Vote Means

• The vote was a recommendation, not a final decision.
• FDA staff had recommended against adding BPC-157, citing a lack of evidence for ulcerative colitis.
• Even if added, being on the compounding list is not the same as FDA approval.

Yes. BPC-157 has been prohibited by the World Anti-Doping Agency (WADA) since 2022 under category S0 (Non-Approved Substances). It’s banned at all times, in and out of competition.

USADA says a therapeutic use exemption for BPC-157 is unlikely to be approved because permitted alternatives exist. It’s also prohibited by the U.S. Department of Defense for service members.

• What is BPC-157 used for? It’s studied for tendon, ligament, muscle, and gut healing, mostly in animal research.
• Does BPC-157 work? Animal studies are promising, but there isn’t enough human research to confirm it works in people.
• Is BPC-157 safe? Its safety in humans hasn’t been established.
• Is BPC-157 legal? It’s not FDA-approved. An FDA advisory committee recommended adding it to the compounding list in July 2026, but the FDA hasn’t finalized that change.
• Is BPC-157 banned for athletes? Yes. It’s prohibited by WADA at all times.
• What does BPC stand for? Body Protection Compound.

• BPC-157 is a 15-amino-acid peptide based on a gastric protein.
• Research is mostly animal-based, with very little human data.
• It’s not FDA-approved, and human safety is still unknown.
• An FDA panel voted 8–6 in July 2026 to recommend it for compounding, but the FDA hasn’t made a final decision.
• It’s banned by WADA for all athletes.

• PMC – Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal (2025)
• AAOS 2025 – Healing or Hype? Systematic Review of BPC-157
• USADA – BPC-157: What Athletes Should Know
• RAPS – FDA Advisory Committee Backs Two Controversial Peptides (July 2026)
• ABC News – FDA Advisory Committee Votes to Add BPC-157 to Compounding List
• JD Supra (Goodwin) – FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides
• Buchanan Ingersoll & Rooney – FDA Voted Yes on Six Peptides: The Regulatory Road Ahead
• BSCG – BPC-157: Rules and Risks for Athletes and Military Service Members